Streetbeat News

Products Services

CTSO

Cytosorbents has received regulatory approval in Taiwan for its CytoSorb device, which is used for the extracorporeal removal of cytokines, bilirubin, and myoglobin from blood. The device is also approved for removing antithrombotic drugs during cardiothoracic surgery to reduce bleeding. CytoSorb will be distributed in Taiwan by Hemoscien Corporation.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:19 am

GTHX

G1 Therapeutics shares are trading lower after the company's PRESERVE 2 Phase 3 trial of Trilaciclib did not achieve statistical significance in the primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:18 am

TRIB

Trinity Biotech has received regulatory approval to conduct an initial European pre-pivotal trial for its next-generation CGM device. The data from this trial will be used to optimize the device ahead of a pivotal trial planned for 2025.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:16 am

ACET

Adicet Bio has received FDA clearance for its IND application for ADI-270, a treatment for renal cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:11 am

TFFP

TFF Pharmaceuticals announced a regulatory update on its TFF TAC clinical program following recent interactions with the FDA. The FDA provided constructive feedback, and the company does not expect significant changes to its timelines or costs. A more detailed update will be provided in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:10 am

RGLS

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced positive topline results from the third cohort of its Phase 1b study of RGLS8429 for ADPKD treatment. The study showed that RGLS8429 was well tolerated and demonstrated a dose response in reducing disease severity markers. Enrollment for the fourth cohort has begun, and the company plans to discuss a potentially pivotal Phase 2/3 study with the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:10 am

COIN

HOOD

MARA

MSTR

RIOT

The anticipated approval of spot Ethereum ETFs could lead to a significant drop in Ether's price, with potential impacts on various crypto-related stocks. Analysts are divided on the potential benefits and consequences of the ETF launch.

Portfolio Pulse from Benzinga Neuro

June 24, 2024 | 11:08 am

RGNX

REGENXBIO has announced the expansion of its AFFINITY DUCHENNE trial to include a new cohort of younger patients. This move aims to broaden the scope of the trial and potentially accelerate the development of treatments for Duchenne Muscular Dystrophy.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:06 am

PGNY

Progyny has acquired Berlin-based fertility benefits platform Apryl to enhance its global fertility and family building care services. The terms of the acquisition were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:06 am

SSNC

SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) has entered a strategic partnership with Marlborough's Investment Fund Services Limited (IFS) to provide fund accounting, middle-office, and transfer agency services for over £16 billion in assets. This partnership involves the transfer of around 90 IFS staff to SS&C and aims to enhance fund administration efficiency using SS&C's technology.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:06 am